These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27149032)

  • 1. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of ramucirumab for the treatment of colorectal cancer.
    Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
    Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
    Javle M; Smyth EC; Chau I
    Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors.
    Sanchez-Gastaldo A; Gonzalez-Exposito R; Garcia-Carbonero R
    Target Oncol; 2016 Aug; 11(4):479-87. PubMed ID: 26887374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
    Fuchs CS; Tabernero J; Tomášek J; Chau I; Melichar B; Safran H; Tehfe MA; Filip D; Topuzov E; Schlittler L; Udrea AA; Campbell W; Brincat S; Emig M; Melemed SA; Hozak RR; Ferry D; Caldwell CW; Ajani JA
    Br J Cancer; 2016 Oct; 115(8):974-982. PubMed ID: 27623234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ramucirumab - a new anticancer agent].
    Telekes A; Deme D
    Orv Hetil; 2016 Oct; 157(40):1587-1594. PubMed ID: 27690622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab and its use in gastric cancer treatment.
    Bronte G; Galvano A; Cicero G; Passiglia F; Rolfo C; Bazan V; Russo A
    Drugs Today (Barc); 2014 Sep; 50(9):613-21. PubMed ID: 25313368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of ramucirumab in the treatment of cancer - A review of literature.
    Vennepureddy A; Singh P; Rastogi R; Atallah JP; Terjanian T
    J Oncol Pharm Pract; 2017 Oct; 23(7):525-539. PubMed ID: 27306885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight.
    Aprile G; Ongaro E; Del Re M; Lutrino SE; Bonotto M; Ferrari L; Rihawi K; Cardellino GG; Pella N; Danesi R; Fasola G
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):165-78. PubMed ID: 25800976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.
    Krupitskaya Y; Wakelee HA
    Curr Opin Investig Drugs; 2009 Jun; 10(6):597-605. PubMed ID: 19513949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
    Garrido M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.
    Calvetti L; Pilotto S; Carbognin L; Ferrara R; Caccese M; Tortora G; Bria E
    Expert Opin Biol Ther; 2015; 15(9):1359-70. PubMed ID: 26190526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab: first global approval.
    Poole RM; Vaidya A
    Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibitors in early development for gastric cancer.
    Pinto MP; Owen GI; Retamal I; Garrido M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab for gastric cancer.
    Shitara K; Ohtsu A
    Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):133-9. PubMed ID: 25431958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.
    Roviello G; Polom K; Roviello F; Marrelli D; Multari AG; Paganini G; Pacifico C; Generali D
    Cancer Invest; 2017 Mar; 35(3):187-194. PubMed ID: 28165839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic agent ramucirumab: meaningful or marginal?
    Wadhwa R; Elimova E; Shiozaki H; Sudo K; Blum MA; Estrella JS; Chen Q; Song S; Ajani JA
    Expert Rev Anticancer Ther; 2014 Apr; 14(4):367-79. PubMed ID: 24605771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies.
    Grabowski J; Glode A
    Am J Health Syst Pharm; 2016 Jul; 73(13):957-68. PubMed ID: 27217518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.
    Spratlin J
    Curr Oncol Rep; 2011 Apr; 13(2):97-102. PubMed ID: 21222245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.